Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate

Itsuki Osawa1 · Koh Okamoto1 · Mahoko Ikeda1,2 · Amato Otani1 · Yuji Wakimoto1 · Marie Yamashita1 · Takayuki Shinozaki1 · Yoshiaki Kanno1 · Daisuke Jubishi1 · Makoto Kurano3 · Sohei Harada1,2 · Shu Okugawa1 · Yutaka Satomi3 · Kyoji Moriya1,2

Accepted: 3 September 2020 / Published online: 12 September 2020 © Springer Science+Business Media, LLC, part of Springer Nature 2020

Abstract
Critical illnesses associated with coronavirus disease 2019 (COVID-19) are attributable to a hypercoagulable status. There is limited knowledge regarding the dynamic changes in coagulation factors among COVID-19 patients on nafamostat mesylate, a potential therapeutic anticoagulant for COVID-19. First, we retrospectively conducted a cluster analysis based on clinical characteristics on admission to identify latent subgroups among fifteen patients with COVID-19 on nafamostat mesylate at the University of Tokyo Hospital, Japan, between April 6 and May 31, 2020. Next, we delineated the characteristics of all patients as well as COVID-19-patient subgroups and compared dynamic changes in coagulation factors among each subgroup. The subsequent dynamic changes in fibrinogen and D-dimer levels were presented graphically. All COVID-19 patients were classified into three subgroups: clusters A, B, and C, representing low, intermediate, and high risk of poor outcomes, respectively. All patients were alive 30 days from symptom onset. No patient in cluster A required mechanical ventilation; however, all patients in cluster C required mechanical ventilation, and half of them were treated with venovenous extracorporeal membrane oxygenation. All patients in cluster A maintained low D-dimer levels, but some critical patients in clusters B and C showed dynamic changes in fibrinogen and D-dimer levels. Although the potential of nafamostat mesylate needs to be evaluated in randomized clinical trials, admission characteristics of patients with COVID-19 could predict subsequent coagulopathy.

Keywords COVID-19 · Anticoagulant · D-dimer · Fibrinogen · Nafamostat mesylate

Highlights
• All patients with COVID-19 treated on nafamostat mesylate were alive at 30 days from symptom onset.
• Using cluster analysis based on clinical characteristics on admission, we identified three subgroups among COVID-19 patients with different clinical presentations of subsequent coagulopathy.
• Clinical characteristics on admission are beneficial in predicting subsequent coagulopathy and consider individualized approaches for thromboembolism.
• Since COVID-19-associated coagulopathy resembles DIC, a careful evaluation of dynamic changes in coagulopathy, as reflected by fibrinogen and D-dimer levels, is essential.

Introduction
Critically ill patients with coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), primarily present with respiratory failure [1]. However, another distinct feature of COVID-19 is its coagulopathy [2, 3]. Coagulopathy, notably increased D-dimer levels, is commonly observed, even on admission, among patients with COVID-19 and is associated with subsequent thromboembolic events and severe outcomes [2–6].
Although the most effective strategy for treating coagulopathy is yet to be established, the International Society of Thrombosis and Haemostasis (ISTH) released an interim guidance that recommended consideration of anticoagulant therapy for all COVID-19 patients, based on limited evidence [7–9].

Although a variety of antiviral agents for COVID-19 has been studied extensively, there has been only one agent, remdesivir, that has proven to be superior to placebo in randomized controlled trials [10, 11]. Among potential agents, nafamostat mesylate (hereafter nafamostat), a serine protease inhibitor, could be one of the promising agents for treating COVID-19. Nafamostat, which provides sufficient prolongation of activated partial thromboplastin time (APTT) without causing major bleeding complications, has been used as an anticoagulant for hemodialysis procedures and disseminated intravascular coagulation (DIC) in Japan and South Korea [12, 13]. Previous in vitro studies revealed that nafamostat blocks the entry of SARS-CoV-2 into the human cell by preventing the fusion of the envelope of SARS-CoV-2 with the host cell [14, 15]. Considering its antiviral and anticoagulant effects, nafamostat may effectively treat COVID-19 patients, particularly those who present with coagulopathy [16]. In light of this, we recently reported a case-series study where 11 critically ill patients with COVID-19 were successfully treated with nafamostat in combination with favipiravir, [17] another antiviral candidate that potentially exhibits activity against SARS-CoV-2 through inhibition of RNA-dependent RNA polymerase [18]. The efficacy of nafamostat alone or in combination with other agents is being evaluated in several phase three randomized trials (jRCTs031200026, NCT04418128, and NCT04352400).

Although many reports have focused on abnormal coagulation parameters on admission, a few others have reported on the subsequent changes in coagulation factors and their association with patient outcomes [4, 19–22]. In this study, we aimed to (1) use clustering analysis to identify the latent subgroups among COVID-19 patients based on their admission characteristics and (2) describe the differences in the subsequent changes in fibrinogen and D-dimer levels among the clusters, while on treatment with nafamostat and favipiravir, to inform strategies that could better control coagulopathy in COVID-19 patients.

Methods

Study design and population

This retrospective descriptive study was conducted at the University of Tokyo Hospital, a tertiary medical center in Tokyo, Japan. We included patients with COVID-19 (aged ≥18 years) who were hospitalized between April 6 and May 31, 2020, and treated with nafamostat (a dose of 0.20 mg/ kg) and favipiravir (a dose of 3600 mg on day 1 and, subsequently, 1600 mg per day) for 14 days or until clinically improved. Additional methylprednisolone for acute respiratory distress syndrome as well as anticoagulants (i.e., intravenous heparin or direct oral anticoagulants) were used at the discretion of each physician. We excluded patients who were on comfort measures. All data were retrospectively retrieved from electronic health records. The presence of SARS-CoV-2 in sputum or nasopharyngeal-swab samples was confirmed using real-time polymerase chain reaction (RT-PCR; Roche, Switzerland). In addition, patients were tested again before discharge when their fever and respiratory symptoms had resolved, because the Japanese governmental policy required two consecutive negative RT-PCR assays before discharge from the hospital to confirm the viral clearance during the study period. The Institutional Review Board of the University of Tokyo approved this study (#3538) and the Institutional Treatment Board of the University of Tokyo Hospital approved the treatment protocol for COVID-19 (#202001CL). The informed consent was obtained from all patients.

Statistical analysis

Cluster analysis

To identify the latent subgroups among COVID-19 patients on admission, we used partitioning around medoids, which is a machine-learning-based clustering approach. On admission, the following variables were used for clustering: demographics [i.e., age, sex, body mass index (BMI), and days from symptom onset to admission], coexisting disorders [i.e., diabetes mellitus, hyperlipidemia, and hypertension], and laboratory data [i.e., PaO₂/FiO₂ ratio, white blood cell (WBC) count, the ratio of lymphocyte to total WBC count, hemoglobin (Hb), platelet count, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (T-Bil), lactate dehydrogenase (LDH), blood urea nitrogen (BUN), serum creatinine (SCr), C-reactive protein (CRP), prothrombin time (PT), APTT, fibrinogen, and D-dimer], which are well-known predictors of severe COVID-19 outcomes, according to past studies [22, 23]. We used Gower’s distance measure to calculate distances between variables and determined the optimal number of clusters using the consensus matrix heatmaps as well as the consensus clustering methods [i.e., the elbow method and cumulative distribution function] [24]. In addition, we visually evaluated the clusters using the t-distributed stochastic neighbor embedding (t-SNE) method [25].

 Springer
Comparisons of COVID-19 subgroups treated with nafamostat

We defined the outcomes of each subgroup as (1) mortality within 30 days from symptom onset, (2) days from admission to two consecutive negative RT-PCR results, and (3) days from symptom onset to two consecutive negative RT-PCR results. To delineate and compare the characteristics, treatments (i.e., the use of favipiravir, methylprednisolone, anticoagulants [i.e., heparin or direct oral anticoagulants, DOAC], mechanical ventilation, venovenous extracorporeal membrane oxygenation, PCR polymerase chain reaction), IQR interquartile range

### Table 1 Characteristics on admission, treatments, and outcomes of all patients treated with nafamostat mesylate and each subgroup

| Characteristics | Overall n = 15 | Cluster A n = 4 | Cluster B n = 5 | Cluster C n = 6 | p value |
|----------------|---------------|----------------|----------------|----------------|---------|
| **Demographics** |               |                |                |                |         |
| Age, median (IQR) | 63.0 (60.0–69.0) | 62.5 (58.3–64.5) | 69.0 (68.0–76.0) | 60.0 (51.3–66.5) | 0.138   |
| Male sex | 4 (100.0) | 3 (60.0) | 6 (100.0) |              | 0.152   |
| BMI, median (IQR) | 23.5 (22.3–26.7) | 23.7 (22.9–25.0) | 22.3 (22.3–23.5) | 25.5 (23.8–28.6) | 0.515   |
| Days from symptom onset to admission (days) (IQR) | 8.00 (7.00–11.0) | 8.00 (7.25–9.00) | 7.00 (7.00–11.0) | 9.50 (8.25–10.8) | 0.798   |
| **Coexisting disorders** |               |                |                |                |         |
| Diabetes mellitus | 0 (0.0) | 0 (0.0) | 1 (20.0) | 2 (33.3) | 0.376   |
| Hyperlipidemia | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (16.7) | 0.152   |
| Hypertension | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0.999   |
| **Laboratory data** |               |                |                |                |         |
| PaO2/FiO2, median (IQR) | 160 (109–241) | 262 (21–293) | 202 (160–228) | 101 (84.5–120) | 0.087   |
| WBC count (/mm3), median (IQR) | 6.00 (5.03–8.30) | 4.90 (4.15–6.22) | 5.60 (4.70–6.60) | 9.05 (6.55–11.3) | 0.087   |
| The ratio of lymphocyte to total WBC, median (IQR) | 14.7 (11.0–18.9) | 17.6 (14.6–20.7) | 14.7 (13.2–17.6) | 11.1 (8.93–16.6) | 0.433   |
| Hemoglobin (g/dL), median (IQR) | 15.0 (13.5–16.4) | 13.6 (13.1–14.5) | 13.8 (12.6–16.4) | 16.2 (15.2–16.4) | 0.183   |
| Platelet count (× 10^4 /mm3), median (IQR) | 20.0 (18.0–27.9) | 20.4 (17.2–23.3) | 19.6 (16.5–25.1) | 25.3 (19.4–30.6) | 0.386   |
| AST (U/L), median (IQR) | 50.0 (41.0–55.5) | 53.0 (44.0–72.0) | 45.0 (39.0–49.0) | 54.5 (45.8–58.0) | 0.328   |
| ALT (U/L), median (IQR) | 38.0 (24.5–55.0) | 57.0 (47.5–58.6) | 35.0 (20.0–38.0) | 41.0 (27.5–52.3) | 0.204   |
| T-Bil (mg/dL), median (IQR) | 0.80 (0.50–0.85) | 0.60 (0.50–0.72) | 0.82 (0.50–0.90) | 0.80 (0.65–1.32) | 0.50    |
| LDH (U/L), median (IQR) | 423 (362–592) | 267 (200–416) | 406 (386–410) | 606 (462–781) | 0.028   |
| BUN (mg/dL), median (IQR) | 19.30 (14.9–27.6) | 20.9 (13.6–27.7) | 21.3 (15.4–27.6) | 19.1 (17.0–21.9) | 0.934   |
| SCr (mg/dL), median (IQR) | 0.92 (0.71–1.03) | 0.97 (0.91–1.06) | 0.92 (0.74–0.92) | 0.76 (0.59–1.01) | 0.543   |
| CRP (mg/dL), median (IQR) | 10.5 (5.42–13.4) | 4.36 (1.43–8.06) | 6.08 (4.76–12.2) | 16.2 (15.2–16.4) | 0.033   |
| PT (seconds), median (IQR) | 12.5 (11.8–13.5) | 11.7 (11.3–12.0) | 12.1 (11.9–13.0) | 13.50 (12.7–13.9) | 0.077   |
| APTT (seconds), median (IQR) | 28.8 (28.2–31.3) | 28.5 (28.2–28.7) | 31.9 (31.7–32.3) | 28.2 (28.0–28.7) | 0.009   |
| Fibrinogen (mg/dL), median (IQR) | 619 (557–683) | 605 (574–641) | 572 (493–761) | 632 (569–686) | 0.99    |
| D-dimer (µg/mL), median (IQR) | 1.30 (0.95–2.40) | 1.00 (0.65–1.83) | 1.10 (1.10–1.20) | 2.60 (1.40–9.72) | 0.078   |
| **Treatments** |               |                |                |                |         |
| Favipiravir | 15 (100.0) | 4 (100.0) | 5 (100.0) | 6 (100.0) | 0.99    |
| Methylprednisolone | 7 (46.7) | 2 (50.0) | 0 (0.0) | 5 (83.3) | 0.022   |
| Anticoagulants (Heparin or DOAC) | 11 (73.3) | 1 (25.0) | 3 (60.0) | 6 (100.0) | 0.165   |
| Mechanical ventilation | 7 (46.7) | 0 (0.0) | 1 (20.0) | 6 (100.0) | 0.001   |
| VV-ECMO | 3 (20.0) | 0 (0.0) | 0 (0.0) | 3 (50.0) | 0.075   |
| **Outcomes** |               |                |                |                |         |
| Mortality within 30 days from symptom onset | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0.99    |
| Days from admission to 2 consecutive negative PCR (days), median (IQR) | 14.5 (10.0–20.8) | 17.0 (13.0–21.3) | 12.5 (8.75–17.3) | 13.0 (10.3–19.5) | 0.620   |
| Days from symptom onset to 2 consecutive negative PCR (days), median (IQR) | 23.0 (21.0–27.8) | 23.5 (22.0–27.0) | 23.5 (18.3–28.8) | 22.5 (21.0–26.3) | 0.684   |

*BMI* body mass index, *WBC* white blood cells, *AST* aspartate aminotransferase, *ALT* alanine aminotransferase, *T-Bil* total bilirubin, *LDH* lactate dehydrogenase, *BUN* blood urea nitrogen, *SCr* serum creatinine, *CRP* C-reactive protein, *PT* prothrombin time, *APTT* activated partial thrombin time, *DOAC* direct oral anticoagulants, *VV-ECMO* venovenous extracorporeal membrane oxygenation, *PCR* polymerase chain reaction, *IQR* interquartile range

*Variables not used for cluster analysis

*bOne patient in cluster C was excluded only from these analyses since the PCR result did not turn negative by 31th May, 2020 (35 days after onset and 30 days after admission)

Values represent n (%), unless otherwise indicated
anticoagulants, mechanical ventilation, and venovenous extracorporeal membrane oxygenation [VV-ECMO]), and outcomes of each cluster, we used Kruskal-Wallis and Fisher’s tests, as appropriate. We constructed line graphs to visualize dynamic changes in fibrinogen and D-dimer levels in patients with COVID-19 and associated coagulopathy from each cluster. In addition, we graphically displayed sequential changes in D-dimer/fibrinogen ratio, a specific marker for embolism [26, 27].

The results of two-tailed tests with P < .05 were considered to be statistically significant. All analyses were conducted using R version 3.6.1 (R Foundation, Vienna, Austria).

Results

Among the 26 patients who were hospitalized, 16 were treated with nafamostat and favipiravir, 6 with favipiravir (primarily due to the limited supply of nafamostat), and 4 without any antiviral agents. One patient on nafamostat and favipiravir and another on no antiviral agents were transitioned to comfort measures soon after admission; thus, they were excluded from the analysis. Among 15 patients in the final cohort (Table 1), the median age was 63.0 years and 13 patients were men. Twelve, seven, and three patients out of fifteen required intensive care, mechanical ventilation, and VV-ECMO, respectively. No patients died nor developed thromboembolic events 30 days from symptom onset. Three patients developed phlebitis at the peripheral intravenous site secondary to nafamostat treatment.

In terms of the clustering approach, we found that the three-class model was optimal, judging from the consensus matrix heatmaps, elbow method, cumulative distribution function curve, and t-SNE plot (Figs. 1, 2). The characteristics and outcomes of all patients and clusters are presented in Table 1. In summary, the patients who belonged to cluster A had high PaO2/FiO2 ratios and low LDH, CRP, and D-dimer levels. The patients who belonged to cluster C were likely to have hyperlipidemia and hypertension. Further, they had low PaO2/FiO2 ratios; high WBC counts; and high LDH, CRP, and D-dimer levels. The levels of patients in cluster B measured between those of the patients in cluster A and cluster C. Accordingly, the patients in cluster A did not require mechanical ventilation and VV-ECMO; however, all patients in cluster C required mechanical ventilation and half of them were treated with VV-ECMO. Nevertheless, there was no significant difference in days from symptom onset or admission to two consecutive negative RT-PCR results among the three subgroups.

Clinical courses of coagulopathy, as reflected by changes in fibrinogen and D-dimer levels, in patients with COVID-19 from each cluster are shown in Fig. 3. In cluster A, D-dimer maintained a low level; however, some critically ill patients in clusters B and C showed dynamic changes in coagulation parameters (e.g., D-dimer level was increasing, while fibrinogen level was decreasing).

Discussion

Using cluster analysis, we statistically classified 15 patients with COVID-19 treated with nafamostat mesylate into 3 subgroups: cluster A, B, and C. Given that low PaO2/FiO2 ratios as well as elevated LDH and D-dimer levels on admission are risk factors for poor outcomes in COVID-19 as per previous studies, [22, 23] the risk for poor outcomes was expected to be low, intermediate, and high for clusters A, B, and C, respectively. In addition, some critical patients in clusters B and C (e.g., patient C-2 on mechanical ventilation and VV-ECMO in Fig. 3) showed dynamic changes in coagulation parameters (i.e., fibrinogen and D-dimer levels).

Several studies to date have described the dynamic changes in coagulation factors during the course of illness [4, 19–22]. Although they summarized their original data in various ways, they consistently revealed a significantly dynamic difference in coagulation factors between survivors and non-survivors as well as a steady increase in D-dimer levels in the early phase (the first 2 weeks of the disease). We described the different patterns of dynamic changes
Consensus clustering methods. 2–1 Elbow method. The elbow method shows the percentage of the variance explained as a function of the number of clusters. The number of clusters should be chosen such a way that adding another cluster does not substantially improve the modeling of the data. The relative change in the area under the cumulative density function (CDF) was high when the number of clusters was three or four (four was better). 2–2 Consensus cumulative distribution function plot. Consensus cumulative distribution function (CDF) is a plot of cumulative density function for consensus values for each number of clusters. The optimal number of clusters is represented by a CDF plot with a first step that is close to 0 followed by a flat plateau up to a second step that is close to 1. The presented consensus CDF plot suggests that four or five clusters were optimal. 2–3 The t-distributed stochastic neighbor embedding (t-SNE) plot is a dimensionality reduction technique that is used to visually simplify high-dimensional data. The left t-SNE plot and right plot showed three and four clusters, respectively. An inspection of each distance between the clusters revealed that three clusters were optimal because cluster 4 in the right plot, which showed four clusters, was located close to cluster 2. Clusters 1, 3, and 2 in the left t-SNE plot are identical to clusters A, B, and C referred to in the text, respectively.
Fig. 3 Dynamic changes in D-dimer levels, fibrinogen levels, and D-dimer/fibrinogen ratios in patients with COVID-19 and associated coagulopathy on nafamostat mesylate. The dynamic changes in D-dimer levels, fibrinogen levels, and D-dimer/fibrinogen ratios among subgroups for 14 days from admission or until discharge are shown. D-dimer/fibrinogen ratios were calculated using the formula: \(\text{[D-dimer (µg/ml)/fibrinogen (mg/dL)] × 100}\)
in coagulation parameters among three subgroups, which were statistically classified, based only on patient characteristics on admission and not on their outcomes. Given that some patients in clusters B and C had noticeable increases in D-dimer levels, patients with specific features (e.g., low \( \text{PaO}_2/\text{FiO}_2 \) ratios; high CRP; and history of diabetes mellitus, hypertension, and hyperlipidemia), even without elevated D-dimer levels on admission, may benefit from preemptive anticoagulation therapy to prevent progressive coagulopathy.

COVID-19-associated coagulopathy resembles DIC and is associated with enhanced fibrinolysis rather than suppressed fibrinolysis as with other infectious-disease-related DIC [2, 3, 16]. As Tang et al. observed that fibrinogen initially increased and then rapidly decreased about 10 days after admission in COVID-19 non-survivors, [4] there may be a transition point from suppressed to enhanced fibrinolysis in the clinical course of COVID-19. Our discovery of some critically ill patients in clusters B and C having an initial increase in D-dimer levels with a subsequent decrease in fibrinogen levels was consistent with Tang et al.’s observation, [4] and these dynamic changes in fibrinogen and D-dimer levels may indicate the development of thromboembolism and subsequent increased risk of hemorrhage. Wichmann et al. reported autopsies revealing that 58% of patients had deep venous thrombosis, unsuspected before death, [28] meaning that new thromboembolism could not be recognized, if not critical. A D-dimer/fibrinogen ratio, calculated using the formula: \( (\text{D-dimer} \ [\mu g/ml] / \text{fibrinogen} \ [mg/dL]) \times 100 \), has proven to be a specific marker for embolism, [26, 27] and the ratio above 1.0 had 94% specificity in the diagnosis of pulmonary embolism in non-COVID-19 patients [26]. Indeed, as shown in Fig. 3, a high D-dimer/fibrinogen ratio (above 1.0 in some patients) may also suggest clinically silent thromboembolism. Fortunately, no patient experienced any critical thromboembolic or hemorrhagic events as within 30 days from their symptom onset. Notwithstanding, monitoring the trend of this ratio as well as fibrinogen and D-dimer levels may be useful in the prediction and management of coagulopathy in COVID-19.

However, our study has the following limitations. First, it is a retrospective, single-arm descriptive study of fifteen patients with COVID-19 treated with nafamostat and favipiravir in an academic hospital. Therefore, it is uncertain if our favorable outcomes are primarily attributable to nafamostat and favipiravir. However, considering that the anti-SARS-CoV-2 effect of nafamostat has been suggested in vitro, [14, 15] its antiviral and anticoagulant activities could work synergistically against COVID-19 with coagulopathy [16, 17]. Second, additional anticoagulants (i.e., intravenous heparin or direct oral anticoagulants), used on some patients, might have contributed to the dynamic changes in fibrinogen and D-dimer levels observed in this study. Third, while there is no definite rule for the minimum sample size for clustering approaches [29] and the indicative variables appear to be distributed appropriately, our small sample size requires extra caution when interpreting our findings. Further studies are needed to confirm our findings.

Conclusions

Using cluster analysis based on their admission status, we statistically classified patients with COVID-19 into three clusters that subsequently had different dynamic changes in fibrinogen and D-dimer levels. Individualized approaches—the use of prophylactic and enhanced anticoagulants when there is high risk of thromboembolism—are necessary together with the careful evaluation of dynamic changes in coagulopathy, as reflected by fibrinogen and D-dimer levels. Further research regarding the effectiveness of nafamostat against COVID-19 and its effects on COVID-19-associated coagulopathy is urgently necessary for guiding physicians towards the optimal treatment strategy.

Acknowledgements

We appreciate all medical staff for their dedication and professionalism in the fight against COVID-19.

Author contributions

IO and KO conceived and designed the study. All authors interpreted the data, critically revised the manuscript, and approved the final manuscript. IO performed statistical analyses, IO and KO drafted the initial manuscript, and KM supervised the study.

Funding

We received no financial support from any organization for the submitted work.

Compliance with ethical standards

Conflict of interest

Dr. Harada reports personal fees from BD, personal fees from Meiji, personal fees from Shionogi, personal fees from Sumitomo Dainippon Pharma, grants and personal fees from MSD, personal fees from Astellas, personal fees from Beckman Coulter Diagnostics, personal fees from FUJIFILM Toyama Chemical, outside the submitted work.

Ethical approval

The Institutional Review Board of the University of Tokyo approved this study (#3538) and the Institutional Treatment Board of the University of Tokyo Hospital approved the treatment protocol for COVID-19 (#202001CL). Informed consent was obtained from all patients.

References

1. Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 395:497–506
2. Levi M, Thachil J, Iba T et al (2020) Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol 7:e438–e440
3. The Lancet H (2020) COVID-19 coagulopathy: an evolving story. Lancet Haematol. https://doi.org/10.1016/s2352-3026(20)30151-4
4. Tang N, Li D, Wang X et al (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haematol 18:844–847
5. Zhang L, Yan X, Fan Q et al (2020) D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. https://doi.org/10.1111/jth.14859
6. Wright FL, Vogler TO, Moore EE et al (2020) Fibrinolysis shutdown correlates to thromboembolic events in severe COVID-19 infection. J Am Coll Surg. https://doi.org/10.1016/j.jamcollsurg.2020.05.007
7. Thachil J, Tang N, Gando S et al (2020) ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 18:1023–1026
8. Connors JM, Levy JH (2020) Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost. https://doi.org/10.1111/jth.14849
9. Tang N, Bai H, Chen X et al (2020) Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 18:1094–1099
10. Beigel JH, Tomashek KM, Dodd LE et al (2020) Remdesivir for the treatment of Covid-19-preliminary report. N Engl J Med. https://doi.org/10.1056/NEJMoa2007764
11. Wang Y, Zhang D, Du G et al (2020) Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet 395:1569–1578
12. Choi JY, Kang YJ, Jang HM et al (2015) Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine 94:e2392
13. Kimura F, Takahashi A, Kitazawa J et al (2020) Successful conservative treatment for massive uterine bleeding with non-septic disseminated intravascular coagulation after termination of early pregnancy in a woman with huge adenomyosis: case report. BMC Womens Health 20:56
14. Hoffmann M, Schroeder S, Kleine-Weber H et al (2020) Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19. Antimicrob Agents Chemother 64:e00754–e00720
15. Yamamoto M, Kiso M, Saki-Tagawa Y et al (2020) The anti-coagulant nafamostat potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and viral infection in vitro in a cell-type-dependent manner. Viruses 12:E629
16. Asakura H, Ogawa H (2020) Potential of heparin and nafamostat combination therapy for COVID-19. J Thromb Haemost 18:1521–1522
17. Doi K, Ikeda M, Hayase N et al (2020) Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series. Crit Care. https://doi.org/10.1186/s13054-020-03078-z
18. Cai Q, Yang M, Liu D et al (2020) Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. https://doi.org/10.1016/j.eng.2020.03.007
19. Wang D, Hu B, Hu C et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected Pneumonia in Wuhu, China. JAMA. https://doi.org/10.1001/jama.2020.1585
20. Li Y, Zhao K, Wei H et al (2020) Dynamic relationship between D-dimer and COVID-19 severity. Br J Haematol. https://doi.org/10.1111/bjh.16811
21. Fu J, Kong J, Wang W et al (2020) The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: a retrospective study in Suzhou China. Thromb Res 192:3–8
22. Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhu, China: a retrospective cohort study. The Lancet 395:1054–1062
23. Wu C, Chen X, Cai Y et al (2020) Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhu, China. JAMA Intern Med. https://doi.org/10.1001/jamainternmed.2020.0994
24. Wilkerson MD, Hayes DN (2010) ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26:1572–1573
25. Maaten LVD, Hinton G (2008) Visualizing data using t-SNE. J Mach Learn Res 9:2579–605
26. Kara H, Bayir A, Degirmenci S et al (2014) D-dimer and D-dimer/fibrinogen ratio in predicting pulmonary embolism in patients evaluated in a hospital emergency department. Acta Clin Belg 69:240–245
27. Hajisadjahi S, Kerman SR, Khojandi M et al (2012) Accuracy of D-dimer/fibrinogen ratio to diagnose pulmonary thromboembolism in patients admitted to intensive care units. Cardiovasc J Afr 23:446–456
28. Wichmann D, Sperhake JP, Lutgehetmann M et al (2020) Autopsy findings and venous thromboembolism in patients with COVID-19. Ann Intern Med. https://doi.org/10.7326/M20-2003
29. Vidman L, Kallberg D, Ryden P (2019) Cluster analysis on high dimensional RNA-seq data with applications to cancer research—an evaluation study. PLoS ONE 14:e0219102

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.